Login Register Cart 0
Generic placeholder image

Current Bioinformatics

Editor-in-Chief

ISSN (Print): 1574-8936
ISSN (Online): 2212-392X

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Predicting Herb-disease Associations Through Graph Convolutional Network

Author(s): Xuan Hu, You Lu, Geng Tian, Pingping Bing, Bing Wang* and Binsheng He*

Volume 18, Issue 7, 2023

Published on: 12 July, 2023

Page: [610 - 619] Pages: 10

DOI: 10.2174/1574893618666230504143647

Price: $65

conference banner
Abstract

Background: In recent years, herbs have become very popular worldwide as a form of complementary and alternative medicine (CAM). However, there are many types of herbs and diseases, whose associations are impossible to be fully revealed. Identifying new therapeutic indications of herbs, that is drug repositioning, is a critical supplement for new drug development. Considering that exploring the associations between herbs and diseases by wet-lab techniques is time-consuming and laborious, there is an urgent need for reliable computational methods to fill this gap.

In this study, we first preprocessed the herbs and their indications in the TCM-Suit database, a comprehensive, accurate, and integrated traditional Chinese medicine database, to obtain the herb-disease association network. We then proposed a novel model based on a graph convolution network (GCN) to infer potential new associations between herbs and diseases.

Methods: In our method, the effective features of herbs and diseases were extracted through multi-layer GCN, then the layer attention mechanism was introduced to combine the features learned from multiple GCN layers, and jump connections were added to reduce the over-smoothing phenomenon caused by multi-layer GCN stacking. Finally, the recovered herb-disease association network was generated by the bilinear decoder. We applied our model together with four other methods (including SCMFDD, BNNR, LRMCMDA, and DRHGCN) to predict herb-disease associations. Compared with all other methods, our model showed the highest area under the receiver operating characteristic curve (AUROC), the area under the precision-recall curve (AUPRC), as well as the highest recall in the five-fold cross-validation.

Conclusion: We further used our model to predict the candidate herbs for Alzheimer's disease and found the compounds mediating herbs and diseases through the herb-compound-gene-disease network. The relevant literature also confirmed our findings.

« Previous
Graphical Abstract

[1]
Nilsson M, Trehn G, Asplund K. Use of complementary and alternative medicine remedies in Sweden. A population-based longitudinal study within the northern Sweden MONICA Project. J Intern Med 2001; 250(3): 225-33.
[http://dx.doi.org/10.1046/j.1365-2796.2001.00882.x] [PMID: 11555127]
[2]
WHO traditional medicine strategy: 2014-2023. Geneva, Switzerland: World Health Organization. 2013.
[3]
Smith T. Herbal dietary supplement sales in US increase 6.8% in 2014. HerbalGram 2015; 107: 52-9.
[4]
He ZY, Jia XB. Gene therapy (Part II). Curr Gene Ther 2020; 20(2): 83-3.
[http://dx.doi.org/10.2174/156652322002200821100006] [PMID: 32951571]
[5]
Yang P. TCM-Suite: A comprehensive and holistic platform for TCM composition identification and network pharmacology analysis. iMeta 2022; 1: e47.
[http://dx.doi.org/10.1002/imt2.47]
[6]
Cheung F. TCM: Made in China. Nature 2011; 480(7378): S82-3.
[http://dx.doi.org/10.1038/480S82a] [PMID: 22190085]
[7]
Huang L, Li X, Guo P, et al. Matrix completion with side information and its applications in predicting the antigenicity of influenza viruses. Bioinformatics 2017; 33(20): 3195-201.
[http://dx.doi.org/10.1093/bioinformatics/btx390] [PMID: 28637337]
[8]
Ma HD, Deng YR, Tian Z, Lian ZX. Traditional Chinese medicine and immune regulation. Clin Rev Allergy Immunol 2013; 44(3): 229-41.
[http://dx.doi.org/10.1007/s12016-012-8332-0] [PMID: 22826112]
[9]
Zhou X, Lu Q, Kang X, Tian G, Ming D, Yang J. protective role of a new polysaccharide extracted from Lonicera japonica Thunb in mice with ulcerative colitis induced by dextran sulphate sodium. BioMed Res Int 2021; 2021: 1-9.
[http://dx.doi.org/10.1155/2021/8878633] [PMID: 33490281]
[10]
Zhou X, Dong Q, Kan X, et al. Immunomodulatory activity of a novel polysaccharide from Lonicera japonica in immunosuppressed mice induced by cyclophosphamide. PLoS One 2018; 13(10): e0204152.
[http://dx.doi.org/10.1371/journal.pone.0204152] [PMID: 30296293]
[11]
Dai Z, Zhu B, Yu H, et al. Role of autophagy induced by arecoline in angiogenesis of oral submucous fibrosis. Arch Oral Biol 2019; 102: 7-15.
[http://dx.doi.org/10.1016/j.archoralbio.2019.03.021] [PMID: 30951892]
[12]
Chaudhari V, Devender P, Hussain Z, Kumar P, Yadav V. Importance of herbal drug for new drug development. J Appl Pharmaceut Sci and Res 2018; 1(4): 19-22.
[13]
Pillai N. Anti-diarrhoeal activity of Punica granatum in experimental animals. Int J pharmacog 1992; 30(3): 201-4.
[http://dx.doi.org/10.3109/13880209209053997]
[14]
Chang-Xiao L, Pei-Gen X. Recent advances on ginseng research in China. J Ethnopharmacol 1992; 36(1): 27-38.
[http://dx.doi.org/10.1016/0378-8741(92)90057-X] [PMID: 1501490]
[15]
Gillis CN. Panax ginseng pharmacology: A nitric oxide link? Biochem Pharmacol 1997; 54(1): 1-8.
[http://dx.doi.org/10.1016/S0006-2952(97)00193-7] [PMID: 9296344]
[16]
Attele AS, Wu JA, Yuan CS. Ginseng pharmacology. Biochem Pharmacol 1999; 58(11): 1685-93.
[http://dx.doi.org/10.1016/S0006-2952(99)00212-9] [PMID: 10571242]
[17]
Kim JH. Cardiovascular diseases and Panax ginseng: A review on molecular mechanisms and medical applications. J Ginseng Res 2012; 36(1): 16-26.
[http://dx.doi.org/10.5142/jgr.2012.36.1.16] [PMID: 23717100]
[18]
Chan GH-h. Ginseng extracts restore high-glucose induced vascular dysfunctions by altering triglyceride metabolism and downregulation of atherosclerosis-related genes. Evid Based Complement Alternat Med 2013; 2013: 797310.
[http://dx.doi.org/10.1155/2013/797310]
[19]
Lee ST, Chu K, Sim JY, Heo JH, Kim M. Panax ginseng enhances cognitive performance in Alzheimer disease. Alzheimer Dis Assoc Disord 2008; 22(3): 222-6.
[http://dx.doi.org/10.1097/WAD.0b013e31816c92e6] [PMID: 18580589]
[20]
Yuan HD, Kim JT, Kim SH, Chung SH. Ginseng and diabetes: The evidences from in vitro, animal and human studies. J Ginseng Res 2012; 36(1): 27-39.
[http://dx.doi.org/10.5142/jgr.2012.36.1.27] [PMID: 23717101]
[21]
Rhee YH, Lee SP, Honda K, Inoué S. Panax ginseng extract modulates sleep in unrestrained rats. Psychopharmacology 1990; 101(4): 486-8.
[http://dx.doi.org/10.1007/BF02244226] [PMID: 2388971]
[22]
Qi C, Wang P, Fu T, et al. A comprehensive review for gut microbes: Technologies, interventions, metabolites and diseases. Brief Funct Genomics 2021; 20(1): 42-60.
[http://dx.doi.org/10.1093/bfgp/elaa029] [PMID: 33554248]
[23]
Boh B. Ganoderma lucidum: A potential for biotechnological production of anti-cancer and immunomodulatory drugs. Recent Patents Anticancer Drug Discov 2013; 8(3): 255-87.
[http://dx.doi.org/10.2174/1574891X113089990036] [PMID: 23227951]
[24]
Boh B, Berovic M, Zhang J, Zhi-Bin L. Ganoderma lucidum and its pharmaceutically active compounds. Biotechnol Annu Rev 2007; 13: 265-301.
[http://dx.doi.org/10.1016/S1387-2656(07)13010-6] [PMID: 17875480]
[25]
Paterson RRM. Ganoderma-A therapeutic fungal biofactory. Phytochemistry 2006; 67(18): 1985-2001.
[http://dx.doi.org/10.1016/j.phytochem.2006.07.004] [PMID: 16905165]
[26]
Ma HT, Hsieh JF, Chen ST. Anti-diabetic effects of Ganoderma lucidum. Phytochemistry 2015; 114: 109-13.
[http://dx.doi.org/10.1016/j.phytochem.2015.02.017] [PMID: 25790910]
[27]
Zeng L, Yang J, Peng S, et al. Transcriptome analysis reveals the difference between “healthy” and “common” aging and their connection with age‐related diseases. Aging Cell 2020; 19(3): e13121.
[http://dx.doi.org/10.1111/acel.13121] [PMID: 32077223]
[28]
Luo H, Wang J, Li M, et al. Drug repositioning based on comprehensive similarity measures and Bi-Random walk algorithm. Bioinformatics 2016; 32(17): 2664-71.
[http://dx.doi.org/10.1093/bioinformatics/btw228] [PMID: 27153662]
[29]
Liu H, Song Y, Guan J, Luo L, Zhuang Z. Inferring new indications for approved drugs via random walk on drug-disease heterogenous networks. BMC Bioinformatics 2016; 17(S17) (Suppl. 17): 539.
[http://dx.doi.org/10.1186/s12859-016-1336-7] [PMID: 28155639]
[30]
Cheng F, Desai RJ, Handy DE, et al. Network-based approach to prediction and population-based validation of in silico drug repurposing. Nat Commun 2018; 9(1): 2691.
[http://dx.doi.org/10.1038/s41467-018-05116-5] [PMID: 30002366]
[31]
Zhou T, Kuscsik Z, Liu JG, Medo M, Wakeling JR, Zhang YC. Solving the apparent diversity-accuracy dilemma of recommender systems. Proc Natl Acad Sci 2010; 107(10): 4511-5.
[http://dx.doi.org/10.1073/pnas.1000488107] [PMID: 20176968]
[32]
Martínez V, Navarro C, Cano C, Fajardo W, Blanco A. DrugNet: Network-based drug–disease prioritization by integrating heterogeneous data. Artif Intell Med 2015; 63(1): 41-9.
[http://dx.doi.org/10.1016/j.artmed.2014.11.003] [PMID: 25704113]
[33]
Huang T. The therapeutic targets revealed by integrative network analysis of noncoding RNAs. Curr Gene Ther 2021; 21(4): 279-9.
[http://dx.doi.org/10.2174/156652322104211018103532] [PMID: 34674619]
[34]
Du B. Predicting LncRNA-disease association based on generative adversarial network. Curr Gene Ther 2021; 22(2): 144-51.
[PMID: 33998988]
[35]
Xu X, Long H, Xi B, et al. Molecular network-based drug prediction in thyroid cancer. Int J Mol Sci 2019; 20(2): 263.
[http://dx.doi.org/10.3390/ijms20020263] [PMID: 30641858]
[36]
Yang J, Peng S, Zhang B, et al. Human geroprotector discovery by targeting the converging subnetworks of aging and age-related diseases. Geroscience 2020; 42(1): 353-72.
[http://dx.doi.org/10.1007/s11357-019-00106-x] [PMID: 31637571]
[37]
Tang X, Cai L, Meng Y, Xu J, Lu C, Yang J. Indicator regularized non-negative matrix factorization method-based drug repurposing for COVID-19. Front Immunol 2021; 11: 603615.
[http://dx.doi.org/10.3389/fimmu.2020.603615] [PMID: 33584672]
[38]
Pei F, Shi Q, Zhang H, Bahar I. Predicting protein–protein interactions using symmetric logistic matrix factorization. J Chem Inf Model 2021; 61(4): 1670-82.
[http://dx.doi.org/10.1021/acs.jcim.1c00173] [PMID: 33831302]
[39]
Luo H, Li M, Wang S, Liu Q, Li Y, Wang J. Computational drug repositioning using low-rank matrix approximation and randomized algorithms. Bioinformatics 2018; 34(11): 1904-12.
[http://dx.doi.org/10.1093/bioinformatics/bty013] [PMID: 29365057]
[40]
Gönen M, Khan S, Kaski S. Kernelized Bayesian matrix factorization. PMLR 2013; 28(3): 864-72.
[41]
Xu J, Meng Y, Peng L, et al. Computational drug repositioning using similarity constrained weight regularization matrix factorization: A case of COVID -19. J Cell Mol Med 2022; 26(13): 3772-82.
[http://dx.doi.org/10.1111/jcmm.17412] [PMID: 35644992]
[42]
Liu C, Wei D, Xiang J, et al. An improved anticancer drug-response prediction based on an ensemble method integrating matrix completion and ridge regression. Mol Ther Nucleic Acids 2020; 21: 676-86.
[http://dx.doi.org/10.1016/j.omtn.2020.07.003] [PMID: 32759058]
[43]
Zheng X. DTI-RCNN: New efficient hybrid neural network model to predict drug–target interactions. In: Kůrková V, Manolopoulos Y, Hammer B, Iliadis L, Maglogiannis I (Eds) Artificial Neural Networks and Machine Learning-ICANN 2018 ICANN 2018 Lecture Notes in Computer Science vol. 11139 Cham: Springer; 2018.2018;
[http://dx.doi.org/10.1007/978-3-030-01418-6_11]
[44]
Liu H, Zhang W, Song Y, Deng L, Zhou S. HNet-DNN: Inferring new drug-Disease associations with deep neural network based on heterogeneous network features. J Chem Inf Model 2020; 60(4): 2367-76.
[http://dx.doi.org/10.1021/acs.jcim.9b01008] [PMID: 32118415]
[45]
Shim J, Hong ZY, Sohn I, Hwang C. Prediction of drug–target binding affinity using similarity-based convolutional neural network. Sci Rep 2021; 11(1): 4416.
[http://dx.doi.org/10.1038/s41598-021-83679-y] [PMID: 33627791]
[46]
Chen S, Liu Z, Li M, et al. Potential prognostic predictors and molecular targets for skin melanoma screened by weighted gene co-expression network analysis. Curr Gene Ther 2020; 20(1): 5-14.
[http://dx.doi.org/10.2174/18755631MTA2oNjg10] [PMID: 32416689]
[47]
Zhao T, Hu Y, Cheng L. Deep-DRM: A computational method for identifying disease-related metabolites based on graph deep learning approaches. Brief Bioinform 2021; 22(4): bbaa212.
[http://dx.doi.org/10.1093/bib/bbaa212] [PMID: 33048110]
[48]
Zhao T, Hu Y, Peng J, Cheng L. DeepLGP: A novel deep learning method for prioritizing lncRNA target genes. Bioinformatics 2020; 36(16): 4466-72.
[http://dx.doi.org/10.1093/bioinformatics/btaa428] [PMID: 32467970]
[49]
Meng Y, Lu C, Jin M, Xu J, Zeng X, Yang J. A weighted bilinear neural collaborative filtering approach for drug repositioning. Brief Bioinform 2022; 23(2): bbab581.
[http://dx.doi.org/10.1093/bib/bbab581] [PMID: 35039838]
[50]
Chen X, Liu MX, Yan GY. Drug–target interaction prediction by random walk on the heterogeneous network. Mol Biosyst 2012; 8(7): 1970-8.
[http://dx.doi.org/10.1039/c2mb00002d] [PMID: 22538619]
[51]
Yang M, Wu G, Zhao Q, Li Y, Wang J. Computational drug repositioning based on multi-similarities bilinear matrix factorization. Brief Bioinform 2021; 22(4): bbaa267.
[http://dx.doi.org/10.1093/bib/bbaa267] [PMID: 33147616]
[52]
Zhao BW, Hu L, You ZH, Wang L, Su XR. HINGRL: Predicting drug–disease associations with graph representation learning on heterogeneous information networks. Brief Bioinform 2022; 23(1): bbab515.
[http://dx.doi.org/10.1093/bib/bbab515] [PMID: 34891172]
[53]
Jiang H, Huang Y. An effective drug-disease associations prediction model based on graphic representation learning over multi-biomolecular network. BMC Bioinformatics 2022; 23(1): 9.
[http://dx.doi.org/10.1186/s12859-021-04553-2] [PMID: 34983364]
[54]
He B, Wang K, Xiang J, et al. DGHNE: Network enhancement-based method in identifying disease-causing genes through a heterogeneous biomedical network. Brief Bioinform 2022; 23(6): bbac405.
[http://dx.doi.org/10.1093/bib/bbac405] [PMID: 36151744]
[55]
Shi X, Young S, Cai K, Yang J, Morahan G. Cancer susceptibility genes: Update and systematic perspectives. Innovation 2022; 3(5): 100277.
[http://dx.doi.org/10.1016/j.xinn.2022.100277] [PMID: 35866046]
[56]
Yang H, Tong F, Qi C, Wang P, Li J, Cheng L. Prioritizing disease-related microbes based on the topological properties of a comprehensive network. Front Microbiol 2021; 12: 685549.
[http://dx.doi.org/10.3389/fmicb.2021.685549] [PMID: 34326821]
[57]
Silva ABOV, Spinosa EJ. Graph convolutional auto-encoders for predicting novel lncRNA-Disease associations. IEEE/ACM Trans Comput Biol Bioinformatics 2021; 19(4): 2264-71.
[58]
Cheng L, Hu Y, Sun J, Zhou M, Jiang Q. DincRNA: A comprehensive web-based bioinformatics toolkit for exploring disease associations and ncRNA function. Bioinformatics 2018; 34(11): 1953-6.
[http://dx.doi.org/10.1093/bioinformatics/bty002] [PMID: 29365045]
[59]
Yang F, Fan K, Song D, Lin H. Graph-based prediction of Protein-protein interactions with attributed signed graph embedding. BMC Bioinformatics 2020; 21(1): 323.
[http://dx.doi.org/10.1186/s12859-020-03646-8] [PMID: 32693790]
[60]
Kipf TN, Welling M. Semi-supervised classification with graph convolutional networks New York: Cornell University. 2016.2016. Available from: https://arxiv.org/abs/1609.02907
[61]
Li G. Deepgcns: Can gcns go as deep as cnns? In. 2019 IEEE/CVF international conference on computer vision (ICCV). Seoul, Korea. 2019; pp. 9266-78. Available from: http://dx.doi.org/10.1109/ICCV.2019.00936
[62]
Li Q, Han Z, Wu X-M. Deeper insights into graph convolutional networks for semi-supervised learning. Proc AAAI Conf Artif Intell 2018; 32(1)
[http://dx.doi.org/10.1609/aaai.v32i1.11604]
[63]
He K, Xiangyu Z, Shaoqing R, Jian S. Deep residual learning for image recognition. Proceedings of the IEEE conference on computer vision and pattern recognition (CVPR) Las Vegas, USA. 2016; pp. 2016; 770-8.
[64]
Yu Z, Huang F, Zhao X, Xiao W, Zhang W. Predicting drug-disease associations through layer attention graph convolutional network. Brief Bioinform 2021; 22(4): bbaa243.
[http://dx.doi.org/10.1093/bib/bbaa243] [PMID: 33078832]
[65]
Huang Y, Hu P, Chan KCC, You ZH. Graph convolution for predicting associations between miRNA and drug resistance. Bioinformatics 2020; 36(3): 851-8.
[http://dx.doi.org/10.1093/bioinformatics/btz621] [PMID: 31397851]
[66]
Berg Rd, Kipf TN, Welling M. Graph convolutional matrix completion. arXiv:170602263, 2017.
[67]
Srivastava N. Dropout: A simple way to prevent neural networks from overfitting. J Mach Learn Res 2014; 15(1): 1929-58.
[68]
Zhang Y, Chen M, Li A, Cheng X, Jin H, Liu Y. LDAI-ISPS: LncRNA–disease associations inference based on integrated space projection scores. Int J Mol Sci 2020; 21(4): 1508.
[http://dx.doi.org/10.3390/ijms21041508] [PMID: 32098405]
[69]
Zhang Y, Chen M, Cheng X, Wei H. MSFSP: A novel miRNA–disease association prediction model by federating multiple-similarities fusion and space projection. Front Genet 2020; 11: 389.
[http://dx.doi.org/10.3389/fgene.2020.00389] [PMID: 32425980]
[70]
Zhang W, Yue X, Lin W, et al. Predicting drug-disease associations by using similarity constrained matrix factorization. BMC Bioinformatics 2018; 19(1): 233.
[http://dx.doi.org/10.1186/s12859-018-2220-4] [PMID: 29914348]
[71]
Yang M, Luo H, Li Y, Wang J. Drug repositioning based on bounded nuclear norm regularization. Bioinformatics 2019; 35(14): i455-63.
[http://dx.doi.org/10.1093/bioinformatics/btz331] [PMID: 31510658]
[72]
Peng L, Tian X, Tian G, et al. Single-cell RNA-seq clustering: Datasets, models, and algorithms. RNA Biol 2020; 17(6): 765-83.
[http://dx.doi.org/10.1080/15476286.2020.1728961] [PMID: 32116127]
[73]
Cai L, Lu C, Xu J, et al. Drug repositioning based on the heterogeneous information fusion graph convolutional network. Brief Bioinform 2021; 22(6): bbab319.
[http://dx.doi.org/10.1093/bib/bbab319] [PMID: 34378011]
[74]
van Laarhoven T, Nabuurs SB, Marchiori E. Gaussian interaction profile kernels for predicting drug–target interaction. Bioinformatics 2011; 27(21): 3036-43.
[http://dx.doi.org/10.1093/bioinformatics/btr500] [PMID: 21893517]
[75]
Wisniewski T, Goñi F. Immunotherapeutic approaches for Alzheimer’s disease. Neuron 2015; 85(6): 1162-76.
[http://dx.doi.org/10.1016/j.neuron.2014.12.064] [PMID: 25789753]
[76]
Isobe C, Abe T, Terayama Y. Levels of reduced and oxidized coenzyme Q-10 and 8-hydroxy-2′-deoxyguanosine in the CSF of patients with Alzheimer’s disease demonstrate that mitochondrial oxidative damage and/or oxidative DNA damage contributes to the neurodegenerative process. J Neurol 2010; 257(3): 399-404.
[http://dx.doi.org/10.1007/s00415-009-5333-x] [PMID: 19784856]
[77]
Togar B, Türkez H, Stefano AD, Tatar A, Cetin D. Zingiberene attenuates hydrogen peroxide-induced toxicity in neuronal cells. Hum Exp Toxicol 2015; 34(2): 135-44.
[http://dx.doi.org/10.1177/0960327114538987] [PMID: 24925361]
[78]
Shahab U, Faisal M, Alatar AA, Ahmad S. Impact of wedelolactone in the anti-glycation and anti-diabetic activity in experimental diabetic animals. IUBMB Life 2018; 70(6): 547-52.
[http://dx.doi.org/10.1002/iub.1744] [PMID: 29624857]
[79]
Safaeian L, Emami R, Hajhashemi V, Haghighatian Z. Antihypertensive and antioxidant effects of protocatechuic acid in deoxycorticosterone acetate-salt hypertensive rats. Biomed Pharmacother 2018; 100: 147-55.
[http://dx.doi.org/10.1016/j.biopha.2018.01.107] [PMID: 29428662]
[80]
Zahroh R. Antihypertension activity test oof red ginger (Zingiber officinale Var. Rubrum Roscoe) ethanol extract by in silico method. J Food Pharmaceut Sci 2021; 9(3): 496-502.
[81]
Choi JR, Kim JH, Lee S, Cho EJ, Kim HY. Protective effects of protocatechuic acid against cognitive impairment in an amyloid beta-induced Alzheimer’s disease mouse model. Food Chem Toxicol 2020; 144: 111571.
[http://dx.doi.org/10.1016/j.fct.2020.111571] [PMID: 32679284]
[82]
Harini R, Pugalendi KV. Antihyperglycemic effect of protocatechuic acid on streptozotocin-diabetic rats. J Basic Clin Physiol Pharmacol 2010; 21(1): 79-91.
[http://dx.doi.org/10.1515/JBCPP.2010.21.1.79] [PMID: 20506690]
[83]
Kaushik-Basu N, Bopda-Waffo A, Talele TT, et al. Identification and characterization of coumestans as novel HCV NS5B polymerase inhibitors. Nucleic Acids Res 2008; 36(5): 1482-96.
[http://dx.doi.org/10.1093/nar/gkm1178] [PMID: 18203743]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy